http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송도미,이승희,신연욱,장혜경,오경숙,전현 효성여자대학교 가정대학 학도호국단 1984 家政大論集 Vol.3 No.-
This study given here presents the results of an experimental investigation of the iron contents contained in the city water which not used for a long time in the winter. The measurements were performed after turning on and for flowing water in a moment. And the quantitative analysis was studied by chemical form and the results were as follows. 1. The content of the ferrous ion was 113.8-14.4 ppm, water soluble iron was 22.5-14.4 ppm and acid soluble iron was 150-10 ppm. 2. Iron contents of the each chemical from gradually reduced but it appeared high value than standard value of city water until five minutes.
홍소현,김도연,김태오,배지윤,이신아 이화여자대학교 의과학연구소 2014 EMJ (Ewha medical journal) Vol.37 No.S
자발성 신파열은 외상 혹은 수술 등의 병력 없이 신장 피막 혹은 신장 주위 혈종이 자발적으로 발생하는 드문 질환으로, 원인으로는 요로 결석[1], 결핵, 신우신염, 신농양 같은 감염성 질환이나[2] 신장의 종양 및 신장 이식 수술 후[3], 후천성 낭성 신환[4] 등이 관련이 있다. 그 중 복막 투석 환자에서 낭성 신질환에 의한 자발성 신파열은 국내 보고가 있었으나 요로감염에 의한 자발성 피막하 혈종을 동반한 신파열은 문헌 보고가 없었다. 저자들은 요로감염으로 진단된 환자에서 피막하 혈종을 동반한 신파열 1례를 경험하였기에 문헌 고찰과 함께 보고하는 바이다.
( Do Youn Oh ),( Yu Jung Kim ),( Yung Jue Bang ),( Jee Hyun Kim ),( In Sil Choi ),( Sae Won Han ),( Seock Ah Im ),( Kyung Hun Lee ),( Tae You Kim ),( Keun Wook Lee ),( Tae Yong Kim ) 대한내과학회 2014 대한내과학회 추계학술대회 Vol.2014 No.1
Background: To investigate the effi cacy of gemcitabine plus UFT (uracil-tegafur) combination chemotherapy as a salvage treatment in patients with metastatic colorectal cancer (MCRC) Methods: This single-arm phase 2 study was conducted at 3 institutions in Korea. Patients with MCRC refractory to fiuoropyrimidine, oxaliplatin and irinotecan were enrolled. Gemcitabine 800 mg/m2 was administered intravenously on days 1, 8 and 15.UFT 200 mg/m2/day was taken orally in 3 divided doses on days 1-21. Cycles were repeated every 4 weeks and tumor evaluation was carried out every 8 weeks. The primary endpoint of this study was 8-week progression-free survival (PFS) rate. Results: Forty-one patients were enrolled. Fourteen patients received gemcitabine/UFT as a third-line treatment and 37 patients as a 4th-line or later-line therapy. Toxicities were easily manageable and non-hematologic toxicities of = grade 3 were rare. The most common toxicity of = grade 3 was neutropenia (20.0%). One patient showed partial response (response rate, 2.4%) and 14 (34.1%) showed stable disease. The 8-week PFS rate was 42.3%. The median PFS was 1.7 months [95% confi dence interval (CI), 1.6-1.8 months] and the median OS was 9.2 months (95% CI, 5.8-12.6 months). Conclusions: Overall effi cacy of gemcitabine/UFT in refractory MCRC was unsatisfactory. However, we could found a minor proportion of patients who showed prolonged tumor stabilization to gemcitabine/UFT. Further studies are warranted to identify a patient subgroup that might have benefi ts from gemcitabine/UFT therapy.
Oh, Do-Youn,Choi, Kui Son,Shin, Hae-Rim,Bang, Yung-Jue The Korean Cancer Association 2009 Cancer Research and Treatment Vol.41 No.2
<P>This study involved a population-based survey to provide evidence of public awareness of risk factors of gastric cancer and to investigate attitudes for the screening of gastric cancer in the South Korean population.</P>
Oh, Do-Youn,Kim, Tae-Yong,Kwon, Jung Hye,Lee, Jae-Jin,Joh, Yohan,Kim, Dong-Wan,Kim, Tae-You,Heo, Dae Seog,Bang, Yung-Jue,Kim, Noe Kyeong Oxford University Press 2005 Japanese journal of clinical oncology Vol.35 No.7
<P><B>Background:</B> Our objective was to verify the efficacy and safety of ‘docetaxel + 5-fluorouracil + cisplatin’ 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.</P><P><B>Methods:</B> Between January and November 2002, we enrolled 43 patients [males 31; median age 55 years (range 24–74)] with inoperable gastric cancer who had not been seen previously in Seoul National University Hospital. The regimen used was docetaxel 70 mg/m<SUP>2</SUP> on day 1, cisplatin 40 mg/m<SUP>2</SUP> on days 2 and 3, and 5-fluorouracil 1200 mg/m<SUP>2</SUP> over 10 h on days 1–3, every 3 weeks.</P><P><B>Results:</B> A total of 168 cycles were administered. Mean cycle number per patient was 3.9. The administered dose intensity of docetaxel was 21.23 mg/m<SUP>2</SUP>/week, 5-FU 1092.14 mg/m<SUP>2</SUP>/week and cisplatin 23.82 mg/m<SUP>2</SUP>/week, which corresponded to 91.1, 91.0 and 89.5% of planned doses. Of the 43 patients, response evaluation was possible in 40 and, of these patients, 17 (42.5%) achieved a partial response, 13 (32.5%) stable disease, and 10 patients (25%) showed progressive disease. The median time to progression was 5.6 months [95% confidence interval (CI) 4.6–6.6 months]. Median overall survival was 9.0 months. (95% CI 4.8–13.2 months). Leukopenia occurred during 21.4% of cycles (36 of 168 cycles); 14.3% grade 1, 5.3% grade 2 and 1.8% grade 3. Anemia occurred in 16.7% (28 of 168 cycles); 11.3% grade 1, 4.8% grade 2 and 0.6% grade 3. Thrombocytopenia was not observed. Diarrhea, stomatitis and hypersensitivity occurred in 4.7% (two out of 43 patients), respectively. Neutropenic fever occurred in two patients (4.7%) and myalgia in three (7.0%).</P><P><B>Conclusion:</B> ‘Docetaxel + 5-fluorouracil + cisplatin’ 3-day combination chemotherapy is an active and tolerable regimen as a first-line treatment in patients with unresectable gastric cancer.</P>
Oh, Do-Youn,Lee, Keun Wook,Lee, Kyung-Hee,Sohn, Chang-Hak,Park, Young Suk,Zang, Dae Young,Ryoo, Hun-Mo,Song, Hong-Suk,Kim, Jin-Soo,Kang, Hye-Jin,Kim, Bong-Seog,Bang, Yung-Jue M. Nijhoff ; Kluwer Academic Publishers 2012 Investigational new drugs Vol.30 No.3
<P>To confirm the efficacy and toxicity of Erlotinib in combination with Gemcitabine and Capecitabine when used as a first-line therapy in metastatic/recurrent pancreatic cancer (PC).</P>